GE Healthcare, NCCS to work on AI research to enhance cancer care

The two parties seek to make cancer treatment more precise.

With 50% of new cancer cases globally in Asia-Pacific, GE Healthcare, a US-based manufacturing firm, and National Cancer Centre Singapore (NCCS) collaborated to focus on an artificial intelligence (AI) research to improve the precision of cancer treatment.

In a joint statement, NCCS, which is under SingHealth, and GE Healthcare agreed to leverage AI and text processing to find more tailored treatment options for specific cancer types and “offer the potential to evaluate clinically significant information along the patient journey for a provider’s efficient decision-making.”

Under their agreement, they will use new AI-powered solutions for data analytics and clinical workflows that support treatment for cancer patients by combining GE Healthcare’s imaging and monitoring expertise and NCCS’s deep expertise in research and development, testing, and consultation.

GE Healthcare CEO Intercontinental Ellie Chaillot said their collaboration also aims to simplify healthcare providers’ decision-making, speed up cancer care delivery, as well as improve patient outcomes.

Globocan, which provides global cancer statistics, said in 2020, there are almost 20 million new cancer cases worldwide, including 9.7 million in the Asia-Pacific region.